TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17671064

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Combined rates of death or disability
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low superior vena cava flow
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low superior vena cava flow and lower gestational age
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low superior vena cava flow and birth weight <10th percentile
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Infants treated with inotropes
Number of subjects: 128
Study: 15826232

Group type: EXPERIMENTAL
Intervention: Task-switch preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time deadlines for optimal advance preparation
Number of subjects: 0
Study: 12138146

Group type: EXPERIMENTAL
Intervention: gentamicin/citrate (40 mg/ml and 3.13% citrate; ratio 2:1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: heparin (5000 U/ml)
Number of subjects: 83
Study: 9570264

Group type: EXPERIMENTAL
Intervention: Hypotonic solution (160 mOsmol/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isotonic solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both hypotonic and isotonic solutions
Number of subjects: 8
Study: 7641409

Group type: EXPERIMENTAL
Intervention: 20 mg oral temazepam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2568767

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4, or 1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.44 +/- 0.11 mg/kg with atracurium and 0.46 +/- 0.12 mg/kg with vecuronium)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (10 subjects allowed to recover spontaneously)
Number of subjects: 90
Study: 31084558

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation at 19.11 J/cm2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation at 25.47 J/cm2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation at 6.37 J/cm2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation at 12.73 J/cm2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (various energy densities)
Number of subjects: 5
Study: 27892890

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10mg OD) plus acetylsalicylic acid (ASA, 75-100mg OD) for 90 days followed by rivaroxaban alone
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Clopidogrel (75mg OD) plus ASA for 90 days followed by ASA alone
Number of subjects: 1520
Study: 25558975

Group type: EXPERIMENTAL
Intervention: Motor control therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General active exercise therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric training therapy
Number of subjects: 0
Study: 24064198

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ABM (Attention Bias Modification)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 22
Study: 21235821

Group type: EXPERIMENTAL
Intervention: 8-week program of intensive unilateral hand training using an instrumented exercise workstation and functional electrical stimulation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 19779321

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 10 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 30 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 100 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 500 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 100 mg once daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 500 mg once daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 750 mg once daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17481461

Group type: EXPERIMENTAL
Intervention: Parents Under Pressure (PUP) program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Brief intervention control group (two-session parenting education intervention)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 64
Study: 15900307

Group type: EXPERIMENTAL
Intervention: Soy supplement (30 g soy protein, 9 g cotyledon fibre, 100 mg isoflavones)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soy supplement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (30 g of casein)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12802453

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with larifan, ridostin, and viferon for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 0
Study: 9796889

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg orally twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8594665

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Untreated bed nets
Number of subjects: 2300
Study: 2569999

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 952692

Group type: EXPERIMENTAL
Intervention: 5 units of oxytocin i.v.
Number of subjects: 148

Group type: COMPARATOR
Intervention: 0.5 mg ergometrine i.v.
Number of subjects: 148
Study: 30976339

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (200 mcg every four hours up to four doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol (200 mcg every four hours up to four doses)
Number of subjects: 100
Study: 27965180

Group type: EXPERIMENTAL
Intervention: Goal-setting plus community health worker support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goal-setting alone
Number of subjects: 0
Study: 25979197

Group type: EXPERIMENTAL
Intervention: 2% CHG/70% IPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% CHG/70% IPA
Number of subjects: 100
Study: 23477506

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 70
Study: 21566054

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 731
Study: 18187561

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 17225012

Group type: EXPERIMENTAL
Intervention: Postoperative solar UV irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No UV exposure (Control)
Number of subjects: 0
Study: 15163340

Group type: EXPERIMENTAL
Intervention: T4/T3 combination therapy (5% of T4 dose substituted by T3)
Number of subjects: 23

Group type: COMPARATOR
Intervention: T4 monotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: T4/T3 combination therapy
Number of subjects: 23
Study: 11339447

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard thoracotomy (Group B)
Number of subjects: 20
Study: 8989173

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 108
Study: 8433182

Group type: EXPERIMENTAL
Intervention: 3-month intervention including consultation for employers on nonsmoking policy, training for nonsmokers to assist smokers, and cessation classes for smokers.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Co-worker support for quitting in the intervention group.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cessation among smokers whose co-workers frequently asked them not to smoke.
Number of subjects: 8
Study: 3318461

Group type: EXPERIMENTAL
Intervention: Diltiazem (Dil)
Number of subjects: 22
Study: 29540324

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic approach (genotyping of ABCB1, CYP2C19*2, and CYP2C19*17)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Standard of care (clinical characteristics alone)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic arm (ticagrelor usage)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Standard-of-care arm (clopidogrel usage)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Both arms (primary composite endpoint)
Number of subjects: 888
Study: 27042193

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Enfuvirtide (ENF)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall incidence of grade 2 or more LEE
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir use
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Elevated ALT at baseline
Number of subjects: 169
Study: 25399892

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 11
Study: 23608085

Group type: EXPERIMENTAL
Intervention: Group A: ropivacaine, epinephrine, ketorolac, and clonidine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group B: ropivacaine, epinephrine, and ketorolac
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group C: ropivacaine, epinephrine, and clonidine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Group D: ropivacaine and epinephrine
Number of subjects: 160
Study: 20466363

Group type: EXPERIMENTAL
Intervention: 0.3 mg conjugated estrogens orally for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5 g conjugated estrogens vaginally for 7 days
Number of subjects: 24
Study: 17694376

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 26
Study: 16650242

Group type: EXPERIMENTAL
Intervention: 5Fr catheter
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6Fr catheter
Number of subjects: 200
Study: 12957559

Group type: EXPERIMENTAL
Intervention: 3-month intervention group (n=10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline control group (n=8)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 3-month control group (n=11)
Number of subjects: 29
Study: 11095657

Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 0
Study: 9123711

Group type: EXPERIMENTAL
Intervention: High-dose yohimbine hydrochloride (36 mg per day orally)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8375223

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Gentamicin/Metronidazole (GM)
Number of subjects: 196
Study: 3788500

Group type: EXPERIMENTAL
Intervention: heparin‐dihydergot
Number of subjects: 181

Group type: COMPARATOR
Intervention: heparin‐acenocoumarin
Number of subjects: 181
Study: 29921153

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) group (n = 325)
Number of subjects: 615

Group type: COMPARATOR
Intervention: No metabolic syndrome group (n = 290)
Number of subjects: 615
Study: 29413356

Group type: EXPERIMENTAL
Intervention: 4g/day of prescription omega‐3 fatty acids (P‐OM3) for 16 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 31
Study: 27095306

Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Sonidegib (various doses from 100 to 3000 mg once daily and 250 to 750 mg twice daily)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg or 800 mg doses)
Number of subjects: 190
Study: 24885374

Group type: EXPERIMENTAL
Intervention: Multi-modal magnetic resonance imaging (MRI) protocol and cognitive assessment
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: MRI brain scan, detailed clinical and cognitive assessment, blood and buccal mucosal samples
Number of subjects: 800
Study: 22281018

Group type: EXPERIMENTAL
Intervention: Test formulation of anastrozole (1 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of anastrozole (1 mg)
Number of subjects: 24
Study: 20498181

Group type: EXPERIMENTAL
Intervention: 5 mg THC twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 18365856

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (1 mg estradiol + 0.125 mg trimegestone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal hormone replacement therapy (150 or 300 microg estradiol + 200 mg micronized progesterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated computer-based analysis
Number of subjects: 0
Study: 15762015

Group type: EXPERIMENTAL
Intervention: Memantine alone or in combination with donepezil
Number of subjects: 656

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 656
Study: 12088976

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV pretreatment with fiberoptic intubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional orotracheal intubation without fentanyl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV pretreatment with conventional laryngoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fiberoptic intubation without fentanyl
Number of subjects: 100
Study: 9536660

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) in three divided doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium valproate (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine (200 mg)
Number of subjects: 0
Study: 8703646

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3338255

Group type: EXPERIMENTAL
Intervention: Strength measured using a dynamometer (Bourdon tube)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Walking speed measured over 100 m
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Leisure activity assessed by questionnaire
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Correlation between strength and walking speed
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Correlation between strength and amount of walking (daily steps)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Increased daily activity
Number of subjects: 122
Study: 29914843

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 284
Study: 28915900

Group type: EXPERIMENTAL
Intervention: α-GalCer-pulsed dendritic cell therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cisplatin plus vinorelbine (standard treatment)
Number of subjects: 56
Study: 26403745

Group type: EXPERIMENTAL
Intervention: SMOF (lipid emulsion formulation containing soybean oil, medium chain triglycerides, olive oil, and fish oil)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medium or long chain lipid emulsion (control)
Number of subjects: 72
Study: 23497590

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standard oral glucocorticoid dosing
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reduced oral glucocorticoid dosing
Number of subjects: 500

Group type: COMPARATOR
Intervention: No plasma exchange
Number of subjects: 500
Study: 20814963

Group type: EXPERIMENTAL
Intervention: Repetition of visual objects in a semantic classification task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial presentation of object names in a separate session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 19919172

Group type: EXPERIMENTAL
Intervention: Around-the-clock (RTC) intervention group (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care group (UCG) of controls (n = 6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study: 17415017

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (identical capsules once daily for 24 weeks)
Number of subjects: 71
Study: 16279282

Group type: EXPERIMENTAL
Intervention: Hormone treatment (unopposed conjugated estrogens (CEE) 0.625 mg/day if without a uterus; CEE combined with medroxyprogesterone acetate (MPA) 2.5 mg/day otherwise)
Number of subjects: 2302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2302
Study: 11930740

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (freezing intercostal nerves for 1.5 minutes)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no cryoanalgesia)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia and Control
Number of subjects: 200
Study: 9559497

Group type: EXPERIMENTAL
Intervention: Ophthimus (High Tech Vision, Malmö, Sweden)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Humphrey (Humphrey Instruments Inc., San Leandro, CA, U.S.A.)
Number of subjects: 21
Study: 7942668

Group type: EXPERIMENTAL
Intervention: Dual therapy with omeprazole 40 mg and amoxicillin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Triple therapy with omeprazole 40 mg, amoxicillin, and metronidazole
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Follow-up of patients with HP eradication
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patients with duodenal ulcers and HP eradication
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 41
Study: 3898514

Group type: EXPERIMENTAL
Intervention: 0.5% solution of epsilon aminocaproic acid (EACA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline plus placebo
Number of subjects: 75
Study: 30040755

Group type: EXPERIMENTAL
Intervention: Standardized scanning and mobility program (7 weeks, 3 times per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individualized therapy recommended by clinicians
Number of subjects: 24
Study: 27255923

Group type: COMPARATOR
Intervention: Existing program with monthly growth monitoring and nutritional/hygiene education (T0)
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: T0 + home visits for intensive nutrition counseling (T1)
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: T1 + lipid-based supplementation (LNS) for children 6-18 months old (T2)
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: T2 + LNS supplementation of pregnant/lactating women (T3)
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: T1 + intensive home visiting program to support child development (T4)
Number of subjects: 3750
Study: 24945932

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg single oral dose
Number of subjects: 0
Study: 22187388

Group type: EXPERIMENTAL
Intervention: Exercise training (8-week program, 3 aerobic sessions per week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 38
Study: 20331739

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT) after immunochemotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No involved-field radiotherapy (non-irradiated) after immunochemotherapy
Number of subjects: 42
Study: 17805230

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (26+/‐5 g protein containing 44+/‐8 mg isoflavones per day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Milk protein isolate (26+/‐5 g protein per day)
Number of subjects: 34
Study: 17574730

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0
Study: 14739037

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 80 mg/m2 on day 1; vindesine 3 mg/m2 on days 1 and 8: x3 courses)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Surgery alone (observation)
Number of subjects: 119
Study: 10967379

Group type: EXPERIMENTAL
Intervention: Adenoid size (hypoplasia or absence)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Early identification of adenoid absence or hypoplasia
Number of subjects: 36
Study: 9131958

Group type: EXPERIMENTAL
Intervention: Ilioinguinal and iliohipogastric nerve block (group A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Penile block (group B)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Caudal block (group C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Metamizol intravenously (group D)
Number of subjects: 76
Study: 8250359

Group type: EXPERIMENTAL
Intervention: carbonated 1% lignocaine (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 to 1 mixture of carbonated lignocaine and bupivacaine (group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adrenaline added to lignocaine
Number of subjects: 60
Study: 2951823

Group type: EXPERIMENTAL
Intervention: Duovent‐Berodual
Number of subjects: 10

Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 10
Study: 30857608

Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Retroclavicular brachial plexus block
Number of subjects: 120
Study: 28275127

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) for 2 years
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (ad libitum consumption)
Number of subjects: 39
Study: 26227186

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus ezetimibe (10 mg) daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 202
Study: 24079283

Group type: EXPERIMENTAL
Intervention: Colesevelam (3750 mg/d) with niacin titration
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo with niacin titration
Number of subjects: 140
Study: 21133824

Group type: EXPERIMENTAL
Intervention: 900 mg allopurinol daily for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100